Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

- PMLiVE

Breaking Bad

Six behaviours separate the good brand teams from the bad

- PMLiVE

The first, my last, my everything

The inescapable rise of patient-centricity

- PMLiVE

J&J’s Invokana first SGLT2 to show kidney disease benefits

Could help revival after amputation risk scare

- PMLiVE

J&J’s targeted bladder cancer treatment gets US approval

Balversa is first FGFR inhibitor

- PMLiVE

Allergan wins support against dissident shareholders

Shareholders vote on 1 May

- PMLiVE

Promethera’s liver failure stem cell therapy clears first hurdle

Technique could be alternative to transplant

- PMLiVE

CAR-T player Autolus seeks $100m from follow-on financing

Funds will further develop pipeline

- PMLiVE

Novo Nordisk and Gilead join forces in NASH

Will combine semaglutide with Gilead’s cilofexor and firsocostat

- PMLiVE

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Mixed efficacy and safety results hits NASH frontrunner

- PMLiVE

No-deal risk recedes, but new Brexit delay adds to uncertainty

Delay means industry must sustain no-deal investment

Vertex: a vision of treating all CF patients worldwide draws closer

Its high prices are controversial, but Vertex also embodies the best of biopharma drug development

- PMLiVE

Galderma launches Rosacea awareness campaign

Campaign comes on the back of Rosacea Awareness Month

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links